Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRX302 in localised prostate cancer
NCT03081481Phase 2Completed
- Sponsor
- Sophiris Bio Inc.
- Start
- Jun 2017
- Primary completion
- Nov 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of topsalysin in prostate cancer (PCa), sponsored by Sophiris Bio Inc. Primary endpoint: Treatment-Emergent Adverse Events at 26 weeks. Started Jun 2017; status: completed.
02
Drugs
topsalysin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03081481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03081481.